Why Modeled Audiences Fail at Finding Rare Disease Patients

The Challenge of Hard-to-Find Audiences

Not all patient populations are created equal. Finding someone interested in a primary care physician or flu vaccine? That's relatively straightforward—the target audience is broad, and the addressable market is large.

But what about patients with ultra-rare diseases? Candidates for specialized oncology treatments? People who need niche surgical procedures performed at only a handful of centers nationwide?

These audiences are different. They're small, dispersed, and incredibly valuable. Finding them requires precision. And that's exactly where modeled audiences break down.

What Are Modeled Audiences?

Before we explain why they fail, let's define what modeled audiences actually are.

Modeled audiences use machine learning algorithms to predict who might have a health condition or need a medical service. The vendor takes known data points—demographics, purchase behavior, web browsing patterns, media consumption—and runs them through a predictive model.

The output is a probability score. This person has a 67% likelihood of having diabetes. That person is 81% likely to need orthopedic care. These "likely condition" segments are then sold to healthcare marketers as ready-made audiences.

For common conditions with large patient populations, modeled audiences can work reasonably well—though they carry significant privacy and compliance risks. But for rare disease and hard-to-find patients? They fail spectacularly. Here's why.

Problem #1: They Guess (And Guessing Isn't Good Enough)

Modeled audiences don't identify patients. They predict who might have a condition and who probably doesn't.

When you're targeting a disease that affects 1 in 10,000 people—or 1 in 100,000—guessing isn't good enough. The margin for error is too small. Actual patients get left out because the algorithm decides they don't fit the pattern.

Why This Happens

Predictive models are trained on patterns. They look for correlations in data—age, geography, income, browsing behavior—and use those patterns to make predictions about who else might fit the profile.

But rare disease patients don't always fit patterns. They're diverse. They span different ages, geographies, and socioeconomic backgrounds. A 22-year-old college student and a 58-year-old executive might both have the same rare condition—but they look nothing alike in the data.

So the model guesses. And because it's optimized for the most common patterns, it misses outliers. It excludes real patients who don't match the statistical norm. For rare disease marketers, that's unacceptable. Every patient matters.

Problem #2: They Age Like Milk

Here's another critical problem with modeled audiences: They can't pick up newly diagnosed patients.

If an audience is built from consumer profiles—static snapshots of demographics, purchase history, and web behavior—refreshing it doesn't change much. The demographics stay the same. The consumer data stays the same. So the algorithm stays the same.

It just keeps spitting out the same list of people.

The Diagnosis Gap

Think about what happens when someone is newly diagnosed with a rare disease. Their demographics don't change. Their purchase history doesn't immediately reflect their diagnosis. Their browsing behavior might shift—but slowly, over weeks or months.

Meanwhile, they need information now. They're searching for treatment options, looking for specialists, and trying to understand their condition. This is the moment when healthcare marketers need to reach them.

But modeled audiences can't see them yet. The model is still working off last month's data—or last quarter's data. By the time the algorithm "catches up," the patient has already made critical decisions about their care.

Problem #3: The Privacy and Compliance Risk

Beyond performance issues, modeled audiences create serious compliance exposure—especially in rare disease and specialty medicine.

State privacy laws increasingly prohibit targeting based on health inferences. Making a prediction about someone's medical condition—even if you never confirm it—is legally risky. And in rare disease, where the conditions themselves are highly sensitive, the risk is amplified.

What Regulators Are Saying

California's attorney general has been clear: Combining personal identifiers with health-related context creates sensitive information—even if it's just an inference. Other states are following suit. Colorado's upcoming AI law specifically targets predictive health models.

For pharmaceutical marketers and rare disease advocacy groups, this isn't theoretical. It's a real compliance risk that modeled audiences introduce into every campaign.

The Fix: Stop Guessing, Start Knowing

If modeled audiences don't work for rare disease and hard-to-find patients, what does?

The answer is simple: Use actual knowledge about groups of people, not predictions about individuals.

What This Means in Practice

Instead of building audiences by guessing who might have a condition, build them around observable, explicit signals:

• People actively searching for information about the condition or treatment
• Engagement with relevant content — disease education sites, patient advocacy groups, medical information resources
• Contextual targeting — reaching people in environments where they're seeking health information
• Declared interests — people who have explicitly opted into receiving information about specific health topics

This approach doesn't rely on demographic patterns or predictive algorithms. It focuses on behavior and context—signals that indicate someone is actively interested in or affected by a condition. And critically, it works for rare disease because it doesn't depend on fitting a statistical pattern.

Why This Approach Works Better

Audiences built on knowledge instead of guesswork deliver three key advantages for rare disease marketers:

1. Higher Accuracy

When you target people based on what they're actually doing—searching for treatment information, engaging with disease-specific content—you reach real patients. Not statistical predictions. Not probabilistic guesses. Actual people who need your message.

2. Captures Newly Diagnosed Patients

Because this approach focuses on current behavior rather than historical consumer profiles, it picks up newly diagnosed patients immediately. The moment someone starts searching for information about their condition, they enter the addressable audience. No lag time. No waiting for algorithms to catch up.

3. Privacy-Safe and Compliant

Targeting based on context and declared interest—rather than health inferences—keeps campaigns compliant with state privacy laws. You're not predicting someone's medical condition. You're reaching them in environments where they're actively seeking health information. That distinction is legally significant.

The result? Better performance, lower compliance risk, and audiences that actually include the patients you're trying to reach.

Real-World Impact: Rare Disease Case Study

Consider a pharmaceutical company launching a treatment for an ultra-rare genetic disorder that affects approximately 5,000 people in the United States. The addressable market is tiny. Every patient matters.

The Modeled Audience Approach (Fails)

A vendor builds a predictive model based on demographics, geography, and consumer behavior patterns. The model identifies 50,000 "likely" patients—but most are false positives. Meanwhile, actual patients who don't fit the demographic pattern are excluded. The campaign wastes budget on the wrong people and misses real patients.

The Knowledge-Based Approach (Works)

Instead, the campaign targets people actively searching for information about the genetic disorder, engaging with disease-specific patient advocacy sites, and participating in relevant online communities. The audience is smaller—but dramatically more accurate. Real patients see the message. Newly diagnosed individuals are reached immediately. Campaign efficiency skyrockets.

This isn't a hypothetical example. It's the reality for rare disease marketers who've moved beyond modeled audiences to knowledge-based targeting. The performance difference is measurable and significant.

Key Takeaways: Modeled Audiences Don't Work for Rare Disease

• Modeled audiences guess — they predict who might have a condition, and guessing isn't good enough for rare disease
• Real patients get excluded — algorithms miss outliers who don't fit statistical patterns, leaving actual patients out
• They age quickly — modeled audiences can't pick up newly diagnosed patients because they rely on static consumer profiles
• Compliance risk is real — health inferences violate state privacy laws, especially in sensitive rare disease contexts
• Knowledge beats guesswork — targeting based on actual behavior and context delivers higher accuracy and better performance
• Privacy-safe alternatives exist — you can reach rare disease patients without predictive models or health inferences